Creative Planning Boosts Stock Holdings in Genmab A/S (NASDAQ:GMAB)

Creative Planning lifted its position in Genmab A/S (NASDAQ:GMAB) by 136.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 47,422 shares of the company’s stock after purchasing an additional 27,353 shares during the quarter. Creative Planning’s holdings in Genmab A/S were worth $1,156,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Capital International Investors increased its stake in Genmab A/S by 7.8% during the first quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after acquiring an additional 315,355 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Genmab A/S by 7.6% during the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after acquiring an additional 103,859 shares in the last quarter. DDD Partners LLC purchased a new position in shares of Genmab A/S during the second quarter valued at $8,860,000. Cubist Systematic Strategies LLC lifted its position in shares of Genmab A/S by 109.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after purchasing an additional 145,689 shares during the period. Finally, Ingalls & Snyder LLC increased its holdings in shares of Genmab A/S by 29.3% in the 2nd quarter. Ingalls & Snyder LLC now owns 229,700 shares of the company’s stock valued at $5,772,000 after acquiring an additional 52,117 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

GMAB has been the subject of a number of analyst reports. Truist Financial decreased their target price on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th. Redburn Atlantic began coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating for the company. Morgan Stanley reaffirmed an “equal weight” rating and set a $31.00 price objective on shares of Genmab A/S in a research note on Wednesday, September 11th. Royal Bank of Canada raised Genmab A/S from a “sector perform” rating to an “outperform” rating in a report on Monday, July 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research note on Wednesday, October 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $22.32 on Friday. Genmab A/S has a 1-year low of $22.22 and a 1-year high of $32.89. The stock’s 50 day simple moving average is $24.97 and its 200-day simple moving average is $26.66. The stock has a market cap of $14.77 billion, a P/E ratio of 18.45, a P/E/G ratio of 0.68 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. The company had revenue of $779.50 million during the quarter, compared to analysts’ expectations of $734.60 million. As a group, research analysts expect that Genmab A/S will post 1.29 EPS for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.